Aeglea BioTherapeutics, Inc. Profile Avatar - Palmy Investing

Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recomb…

Biotechnology
US, Austin [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of AGLE's Analysis
CIK: 1636282 CUSIP: 00773J103 ISIN: US00773J2024 LEI: - UEI: -
Secondary Listings
AGLE has no secondary listings inside our databases.